Filing Details

Accession Number:
0001567619-23-004543
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-06 18:54:26
Reporting Period:
2023-03-02
Accepted Time:
2023-03-06 18:54:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1787306 Arcutis Biotherapeutics Inc. ARQT Pharmaceutical Preparations (2834) 812974255
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1840191 Richard Matthew Moore C/O Arcutis Biotherapeutics, Inc.
3027 Townsgate Road, Suite 300
Westlake Village CA 91361
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-03-02 1,589 $15.82 11,711 No 4 S Direct
Common Stock Disposition 2023-03-02 21 $16.52 11,690 No 4 S Direct
Common Stock Acquisiton 2023-03-02 14,900 $0.00 26,590 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2023-03-02 39,500 $0.00 39,500 $15.82
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
39,500 2033-03-02 No 4 A Direct
Footnotes
  1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
  2. The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2024, subject to the Reporting Person's continued service to the Issuer.
  4. 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.